Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Researchers from the UK have been studying the BCG (Bacillus Calmette-Guérin) vaccine, which has been widely used to protect against tuberculosis (TB).
Tuberculosis (TB) is a disease caused by a bacterium called Mycobacterium tuberculosis. A person can be infected with the bacterium without it developing into a disease. This is known as latent TB. The risk of the infection developing into the TB disease can sometimes be decreased by the standard BCG vaccine. However, little is known about the vaccine’s role in fighting initial TB infection.
In their study, published in the British Medical Journal, the researchers investigated whether BCG can also protect against the initial TB infection. They analysed a range of research into the effect of BCG on children under the age of 16, completed between 1950 and 2013. These studies were carried out in a range of countries in Europe, Asia and Africa.
The researchers found that, upon exposure to the bacteria that causes TB, children who had been vaccinated with the BCG vaccine had a 19% chance of being protected against infection, compared with children who weren’t vaccinated. In addition, the vaccine seemed to be more effective in European countries than those in Asia and Africa.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description